ElectroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
ElectroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.
新澤西州洛克威，2023年11月7日（GLOBE NEWSWIRE）——商業階段的生物電子醫療和保健公司ElectroCore, Inc.（納斯達克股票代碼：ECOR）今天宣佈，公司首席執行官丹·戈德伯格計劃參加2023年11月16日在紐約大中央威斯汀酒店舉行的Canaccord Genuity MedTech、診斷和數字健康與服務論壇。
1x1 Meetings
1x1 會議
electroCore will host 1x1 investor meetings on November 16, 2023. Please contact your Canaccord representative to schedule a 1x1 meeting.
ElectroCore將於2023年11月16日舉辦1x1投資者會議。請聯繫您的 Canaccord 代表安排 1x1 會議。
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
關於 ElectroCore, Inc.
ElectroCore, Inc. 是一家商業階段的生物電子醫學和健康公司，致力於通過其非侵入性迷走神經刺激（“nVN”）技術平台改善健康。我們的重點是將用於管理和治療某些疾病的醫療器械的商業化，以及利用NVN促進美國和部分海外市場的總體健康和人類績效的消費品產品。
For more information, visit .
欲了解更多信息，請訪問。
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
聯繫人：
ECOR 投資者關係
(973) 302-9253
investors@electrocore.com
譯文內容由第三人軟體翻譯。